Sentinel Trust Co. LBA Grows Holdings in Zoetis Inc. (NYSE:ZTS)

Sentinel Trust Co. LBA raised its position in Zoetis Inc. (NYSE:ZTS) by 53.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,951 shares of the company’s stock after buying an additional 1,733 shares during the period. Sentinel Trust Co. LBA’s holdings in Zoetis were worth $807,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Callahan Advisors LLC grew its stake in Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after purchasing an additional 6,221 shares in the last quarter. Pensionfund Sabic boosted its stake in shares of Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after buying an additional 4,000 shares during the last quarter. PFW Advisors LLC acquired a new stake in shares of Zoetis during the fourth quarter worth approximately $1,764,000. CIBC Asset Management Inc grew its position in shares of Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after buying an additional 46,050 shares in the last quarter. Finally, Alberta Investment Management Corp increased its stake in shares of Zoetis by 2,050.0% in the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after buying an additional 28,700 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Zoetis Price Performance

Shares of NYSE ZTS opened at $164.95 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The firm has a market capitalization of $73.86 billion, a PE ratio of 30.16, a P/E/G ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The business’s fifty day moving average price is $166.25 and its two-hundred day moving average price is $177.49.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.21%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target on the stock. Piper Sandler boosted their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Thursday. Stifel Nicolaus reduced their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, Morgan Stanley decreased their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.